Okay, the user provided a question about the enzyme deficiency in Fabry disease. Let me start by recalling what I know about Fabry disease. It's a lysosomal storage disorder, right? Caused by the deficiency of an enzyme that breaks down specific lipids. The enzyme involved here is alpha-galactosidase A.

So the core concept here is lysosomal storage diseases, specifically Fabry. The key is knowing which enzyme is deficient. The question is straightforward but important for exam prep.

The correct answer should be alpha-galactosidase A. Let me verify. Fabry disease is due to the deficiency of this enzyme, leading to the accumulation of globotriacontosylceramide (Gb3) in various tissues. That's why patients present with symptoms like acroparesthesias, angiokeratomas, and renal issues.

Now, the wrong options. Let's think about other lysosomal enzymes. For example, beta-glucocerebrosidase is deficient in Gaucher disease. Arylsulfatase A is the issue in Metachromatic leukodystrophy. And alpha-L-iduronidase is deficient in Hunter syndrome. So each of these options would be incorrect here.

The clinical pearl is that Fabry disease is X-linked recessive, so it's more common in males. Also, enzyme replacement therapy is a treatment option. Patients might have a family history and characteristic skin lesions.

I need to structure the explanation clearly, making sure each section is concise. Check the character count to stay within the limit. Let me make sure the key terms are bolded and the sections are properly labeled without markdown headers. Also, avoid repeating the question and stick to the required sections.

**Core Concept**
Fabry disease is an X-linked recessive lysosomal storage disorder caused by the deficiency of **alpha-galactosidase A**, leading to the accumulation of **globotriacontosylceramide (Gb3)** in vascular endothelial cells and various organs. This results in systemic manifestations like acroparesthesias, angiokeratomas, and renal failure.

**Why the Correct Answer is Right**
The deficiency of **alpha-galactosidase A** impairs the breakdown of Gb3, a glycosphingolipid. Accumulation of Gb3 in lysosomes damages endothelial cells, causing microvascular ischemia, pain crises, and progressive organ dysfunction (e.g., cardiomyopathy, nephropathy). Enzyme replacement therapy with agalsidase beta or alpha is the standard treatment.

**Why Each Wrong Option is Incorrect**
**Option A:** Beta-glucocerebrosidase deficiency causes **Gaucher disease**, not Fabry.
**Option B:** Arylsulfatase A deficiency leads to **metachromatic leukodystrophy**, characterized by sphingomyelin accumulation.
**Option C:** Alpha-L-iduronidase deficiency is seen in **Hurler syndrome (MPS I)**, causing glycosaminoglycan storage.

**Clinical Pearl / High-Yield Fact**
Remember **"Fabry’s triad"**: acroparesthesias (painful burning extremity pain), angiokeratomas (red-brown skin lesions), and corneal clouding. Early diagnosis is critical to prevent end-stage renal disease. **En

✓ Correct Answer: C. α Galactosidase